Sfoglia per RIVISTA
CANCER MEDICINE
Collezione AOU San Luigi di Orbassano
Items : 4
Molecular response and quality of life in chronic myeloid leukemia patients treated with intermittent TKIs: First interim analysis of OPTkIMA study. in Cancer medicine / Cancer Med. 2021 Mar;10(5):1726-1737. doi: 10.1002/cam4.3778. Epub 2021 Feb 16.
2021
AOU San Luigi di Orbassano
AOU Novara
AOU Alessandria
De Vivo A; Baccarani M; Roccaro AM; Polverelli N; Bernardi S; Farina M; Gandolfi L; Bocchia M; Aprile L; Russo S; Russo Rossi A; Tiribelli M; Rege Cambrin G; Romano A; Coppi MR; Corsetti MT; Rosti G; Sancetta R; Lemoli RM; Castagnetti F; Lunghi F; Ferrari ML; Crugnola M; Lunghi M; D'Adda M; Binotto G; Stagno F; Abruzzese E; Bonifacio M; et alii...
The neutrophil to lymphocyte ratio (NLR) and the presence of large nodal mass are independent predictors of early response: A subanalysis of the prospective phase II PET-2-adapted HD0607 trial. in Cancer medicine / Cancer Med. 2020 Dec;9(23):8735-8746. doi: 10.1002/cam4.3396. Epub 2020 Nov 6.
2020
AOU San Luigi di Orbassano
AO Cuneo
AOU Città della Salute di Torino
Gallamini A; Rambaldi A; Massimo Gianni A; Chauvie S; Biggi A; Ferreri AJM; Viero P; Gini G; Zanotti R; Parvis G; Schiavotto C; Cimminiello M; Corradini P; Zoli V; Gavarotti P; Bolis S; Trentin L; La Nasa G; Cantonetti M; Picardi M; Rossi A; Patti C; Viviani S; Tarella C; Di Raimondo F; Pavoni C; Romano A;
Self-evaluation of duration of adjuvant chemotherapy side effects in breast cancer patients: A prospective study. in Cancer medicine / Cancer Med. 2018 Sep;7(9):4339-4344. doi: 10.1002/cam4.1687. Epub 2018 Jul 20.
2018
ASL Cuneo 2
ASL Torino 4
ASL Asti
AOU San Luigi di Orbassano
ASL VCO
AO Cuneo
AOU Città della Salute di Torino
ASL Città di Torino
ASL Vercelli
AOU Novara
Montemurro F; Aglietta M; Ballari AM; Tealdi G; Giuliano PL; Parola G; Bertola G; Grasso B; Volpone C; Calori A; Solinas G; Foresto M; Berchialla P; Longo V; Martinello R; Cagnazzo C; Milani A; Geuna E; Galizia D;
Prognostic impact of the cumulative dose and dose intensity of everolimus in patients with pancreatic neuroendocrine tumors. in Cancer medicine / Cancer Med. 2017 Jul;6(7):1493-1499. doi: 10.1002/cam4.1028. Epub 2017 May 25.
2017
AOU San Luigi di Orbassano
Berardi R; Torniai M; Pusceddu S; Spada F; Ibrahim T; Brizzi MP; Antonuzzo L; Ferolla P; Panzuto F; Silvestris N; Partelli S; Ferretti B; Freddari F; Gucciardino C; Testa E; Concas L; Murgioni S; Bongiovanni A; Zichi C; Riva N; Rinzivillo M; Brunetti O; Giustini L; Di Costanzo F; Delle Fave G; Fazio N; De Braud F; Falconi M; Cascinu S; et alii...